Central Nervous System

FDA greenlights Neuralink for human trials

The US Food and Drug Administration (FDA) has approved Neuralink for its first in-human study. In a Twitter announcement, the…

BIAL R&D doses first patient in ACTIVATE study of BIA 28-6156

BIAL R&D has dosed the first patient in its Phase II ACTIVATE study of BIA 28-6156 to treat patients with…

Cybin doses first healthy volunteers in Part C of CYB004 study

Cybin has dosed the first healthy volunteers in the ongoing Part C of Phase I study of CYB004 to treat…

First subjects in IBC’s Phase Ib trial receive IBC-Ab002

ImmunoBrain Checkpoint (IBC) has announced the dosing of the first two patients in a Phase Ib trial of IBC-Ab002 to…

First patient dosed in Inhibikase’s Phase II Parkinson’s disease trial

Inhibikase Therapeutics has dosed the first patient in a Phase II ‘201’ clinical trial of IkT-148009 for the treatment of…

Roche’s BTK inhibitor succeeds in a Phase II MS trial

Roche’s fenebrutinib achieved positive results in a Phase II clinical trial in patients with relapsing forms of multiple sclerosis (RMS),…

Coya Therapeutics reports positive data from small Alzheimer’s disease trial

Coya Therapeutics has announced positive data from a small trial in Alzheimer’s disease as the company looks to build out…

Pipeline Moves: Hengrui Medicine Phase III breast cancer termination lowers approval prospects

This week on Pipeline Moves, we start by investigating terminations of a Phase III trial in breast cancer, a Phase…

NeuroSense makes key progress in Phase II ALS trial

NeuroSense Therapeutics has completed enrolment of a Phase IIb trial in amyotrophic lateral sclerosis (ALS), marking an important milestone in…

Larimar reports results from Friedreich’s ataxia drug trial

US-based biotechnology company Larimar Therapeutics has reported preliminary top-line results from a trial of CTI-1601 for the treatment of Friedreich’s…